ClinicalTrials.gg

Program

PN20

A development code.

Its studies are mostly in Thrombocytopenia · Purpura, Thrombocytopenic, Idiopathic, led by Chongqing Peg-Bio Biopharm.

Furthest: phase 2, since Feb 26, 20263 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Peg-Bio Biopharm30 open or runningphase 2since Feb 26, 2026Jul 18, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 18, 2024First studies: 2 phase 1 studiesFirst studyNCT06521931, NCT06523088
  2. Feb 26, 2026Phase 2 study in ThrombocytopeniaPhase 2 reachedNCT07446491 · 54 enrolled · China
  3. Oct 22, 2026Primary completion moved from 2026-05-30 to 2026-10-10Date moved laterphase 2 · +4 months · NCT07446491

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07446491Thrombocytopenia · China2CompletedOct 10, 202654
NCT06523088Purpura, Thrombocytopenic, Idiopathic · China1CompletedJan 5, 202327
NCT06521931Thrombocytopenia · China1CompletedJan 13, 202524

How it is read

Names in the registry

  • “PN20”, 3 entries

Codes read as this program: PN20.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.